Jared Weiss, MD

Articles

Dr. Weiss on the Design of the KRYSTAL-10 Trial in KRAS G12C-Mutated CRC

January 17th 2022

Jared Weiss, MD, discusses the design of the phase 3 KRYSTAL-10 trial in KRAS G12C-mutated unresectable or metastatic colorectal cancer.

Dr. Weiss on the Rationale for the KRYSTAL-1 Trial in KRAS G12C–Mutated CRC

October 19th 2021

Jared Weiss, MD, discusses the rationale for the phase 1/2 KRYSTAL-1 trial in patients with KRAS G12C–mutated colorectal cancer.

Dr. Weiss on the Efficacy Results of the KRYSTAL-1 Trial in KRAS G12C–Mutated CRC

September 29th 2021

Jared Weiss, MD, discusses the efficacy results of the ongoing phase 1/2 KRYSTAL-1 trial in KRAS G12C–mutated colorectal cancer.

Next Steps in Managing Chemo-Induced Myelosuppression

September 16th 2021

Trials of interest exploring various novel therapies as chemoprotection in patients with solid tumor cancers.

Expanded Access to Trilaciclib for Patients With ES-SCLC

September 16th 2021

Jared Weiss, MD, reacts to new measures that increase patient access and provider reimbursement to trilaciclib for patients with extensive-stage small cell lung cancer.

Trilaciclib: Treatment Considerations

September 16th 2021

Advantages associated with the administration of trilaciclib in appropriate patients receiving a chemotherapy-containing regimen for extensive-stage small cell lung cancer.

ES-SCLC: Trilaciclib for Chemo-Induced Myelosuppression

September 9th 2021

Jared Weiss, MD, of UNC Lineberger Comprehensive Cancer Center, highlights clinical trial data that led to the approval of trilaciclib in patients receiving a chemotherapy-containing regimen for extensive-stage small cell lung cancer.

Myelopreservation With CDK4/6 Inhibitors

September 9th 2021

The rationale for using CDK4/6 inhibitors to prevent myelosuppression in patients receiving chemotherapy-containing regimens for extensive-stage small cell lung cancer.

Limitations When Managing Chemo-Induced Myelosuppression

September 2nd 2021

Pros and cons of strategies used to manage chemotherapy-induced myelosuppression in extensive-stage small cell lung cancer.

Guidelines for Managing Chemo-Induced Myelosuppression in ES-SCLC

September 2nd 2021

Guidance for managing chemotherapy-induced myelosuppressive events in patients with extensive-stage small cell lung cancer based on risk stratification criteria, available therapies, and prophylaxis options.

Clinical Impact of Chemo-Induced Myelosuppression in ES-SCLC

August 26th 2021

Drs Charu Aggarwal and Jared Weiss react to the impact that chemotherapy-induced myelosuppression can have on patients with extensive-stage small cell lung cancer, as well as the overall health system.

Chemo-Induced Myelosuppression in ES-SCLC

August 26th 2021

Types of chemotherapy-induced myelosuppression that typically occur in patients with extensive-stage small cell lung cancer and considerations for treating patients based on risk factors and presentation of adverse events.

Dr. Weiss on the FDA Approval of Trilaciclib in Small Cell Lung Cancer

February 12th 2021

Jared Weiss, MD, discusses the FDA approval of trilaciclib in small cell lung cancer.

Dr. Weiss Discusses the Impact of Immunotherapy on Head and Neck Cancer

March 30th 2018

Jared Weiss, MD, assistant professor, UNC Lineberger Comprehensive Cancer Center, discusses the impact of immunotherapy in head and neck cancer.

Dr. Weiss on the Design of the PACIFIC Trial

March 9th 2018

Jared Weiss, MD, associate professor, School of Medicine, UNC Chapel Hill, UNC Lineberger Comprehensive Cancer Center, discusses the clinical applications of the phase III PACIFIC trial in non–small cell lung cancer in the United States.

Dr. Weiss Discusses When to Biopsy in Lung Cancer

November 18th 2017

Jared Weiss, MD, assistant professor, UNC Lineberger Comprehensive Cancer Center, discusses how and when to biopsy patients for lung cancer.

Dr. Weiss Discusses Prevention in Head and Neck Cancer

August 14th 2017

Jared Weiss, MD, assistant professor, UNC Lineberger Comprehensive Cancer Center, discusses prevention in head and neck cancer.

Dr. Weiss on Developments in the Treatment of Head and Neck Cancer

August 10th 2017

Jared Weiss, MD, assistant professor, UNC Lineberger Comprehensive Cancer Center, discusses developments of immunotherapy trials for patients with head and neck cancer.

Dr. Weiss on the Role of Immunotherapy in Head and Neck Cancer

August 3rd 2017

Jared Weiss, MD, assistant professor, UNC Lineberger Comprehensive Cancer Center, discusses the role of immunotherapy in head and neck cancer.

Dr. Weiss on Immunotherapy Combinations in Head and Neck Cancer

July 25th 2017

Jared Weiss, MD, assistant professor, UNC Lineberger Comprehensive Cancer Center, discusses immunotherapy combinations in head and neck cancer.